In this study, all patients were adenocarcinoma with sensitive EGFR mutations, 98% had a relatively good ECOG PS score of 0-1 and the median age of all patients was 58 years, which made the results of this study comparable to LUX-Lung 3 and 6 trials (Sequist et al., 2013; Wu et al., 2014) . Here, EGFR is linked to adenocarcinoma.